Drugs / i15.NKG2D.zeta-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07211737 | Aug 2026 → Apr 2029 expected | neuroblastoma, osteosarcoma | Baylor College of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | i15.NKG2D.zeta-NK cells | “The C7R.GD2.CAR-T cells and i15.NKG2D.zeta-NK cells are investigational products not approved by the Food and Drug Administration.” NCT07211737 ↗ |
| Modality | Cell therapy | “This is a gene transfer research study using special immune cells called NK cells and T cells.” NCT07211737 ↗ |
| Route | Intravenous | “the patient will be given an injection of i15.NKG2D.zeta-NK cells into the vein through an IV line at the assigned dose.” NCT07211737 ↗ |